CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device
TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. ("CellAegis" or the "Company"), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial ("CONDI 2") to further assess the efficacy of remote ischemic conditioning ("RIC") in reducing clinical events in patients presenting with ST-segment-elevation myocardial infarction ("STEMI") and receiving point of care treatment by paramedics in an ambulance. This trial utilized CellAegis' autoRIC® (http://cellaegis.com/products/) device to deliver the RIC therapy.
CONDI 2 is a multinational, randomized, controlled, single-blind, parallel assignment clinical trial which enrolled 2,600 STEMI patients in ambulances in Denmark, Serbia, and Spain. The study was sponsored by the Aarhus University Hospital in Denmark and is designed to show the benefit of RIC versus standard of care treatment in reducing cardiac death and hospitalization for heart failure at twelve months in STEMI patients.
Data from the CONDI 2 trial is expected to augment existing positive evidence related to the therapeutic benefits of RIC in the treatment of cardiovascular disease and procedure related kidney damage. CellAegis currently expects to report the topline results of CONDI 2 trial in mid- 2019.
Meta-analysis of multiple previous studies has shown that RIC significantly reduced infarct (dead tissue) size by 43% (Journal American Heart Association: McLeod et al 2017). In a recent prospective trial conducted in 448 patients at Hospital de Braga in Portugal (Basic Research Cardiology: Gaspar et al 2018), RIC treatment was also shown to reduce heart failure/cardiac death events by 62% at two years.
"The portability and ease of use of the autoRIC® device fit seamlessly into the ambulance setting," said Hans Erik Bøtker, MD, PhD, FESC, FACC, Professor of Cardiovascular Medicine and Interventional Cardiology and co-director of Department of Cardiology, Aarhus University Hospital Skejby, the principal investigator for CONDI 2. "The autoRIC's fully automated features allows emergency response professionals to deliver a novel, non-invasive therapy while focusing on other patient care needs."
"More than 2.9 million patients worldwide are hospitalized each year with an acute coronary syndrome," said Rocky Ganske, Chief Executive Officer, CellAegis. "One-third of those patients have STEMI, which may lead to heart failure. While there has been advancement in the treatment of these patients utilizing PCI and other therapies, there is no question that significant unmet medical need remains. This trial, with over 2,600 patients, is unprecedented in size for medical devices, and if the outcome is positive, as the company anticipates, we believe autoRIC® has the potential to change the standard of care for STEMI patients."
"This trial, in combination with a large UK hospital STEMI trial ("ERIC-PPCI") and our US FDA registration trial ("SHIELD"), is expected to definitively demonstrate whether RIC can improve outcomes for patients with STEMI or undergoing elective PCI procedures while at the same time lowering patient treatment costs. Data from these trials is expected to drive expanded adoption of the autoRIC® device in Europe followed by the U.S.," continued Mr. Ganske.
RIC is a noninvasive therapy that utilizes four cycles of limb occlusion and reperfusion to protect the heart and other tissue against ischemia-reperfusion injury. RIC is a promising adjunctive treatment to stenting in the prevention of ischemic-reperfusion injury and minimization of post-infarct heart failure in ST-elevation myocardial infarction ("STEMI") patients. Previous proof-of-concept clinical studies with RIC have demonstrated improvements in markers of injury, such as increased myocardial salvage and reduced infarct size as well as reduction of contrast-induced acute kidney injury, in various clinical scenarios such as heart attacks and elective cardiac procedures.
About CellAegis Devices
CellAegis Devices, headquartered in Toronto, Canada, is the world leader in automated remote ischemic conditioning. The company has patented and developed the non-invasive autoRIC® device, which delivers RIC therapy to patients with acute and chronic cardiovascular conditions. The autoRIC device® has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures, and is currently limited to investigational use in the United States. Investigator sponsored clinical research studies for chronic conditions such as heart failure and stroke are also underway. The autoRIC® device was developed from the clinical work of clinicians and researchers at Toronto's world-renowned Hospital for Sick Children.
This press release may contain forward-looking statements identified by words such as "expects", "anticipates", "will" and similar expressions, which reflect CellAegis' current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. The forward-looking statements are made as of the date of this press release and CellAegis does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise, except as required by law.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellAegis Devices Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
YouGov poll reveals UK adults are seeking innovative, digital payment experiences from their banks16.7.2018 01:04 | Pressmeddelande
New research showcases a list of innovative ways we'd like better protection against fraud and a more active role in controlling our payment cards· Switching cards on and off for better fraud controls, quickly reactivating blocked cards and mobile app based self-service is the future London, UK, July 16, 2018 (GLOBE NEWSWIRE) -- UK adults are ready for real-time interaction with their banks. The results of a recent YouGov survey, on behalf of Ondot, revealed today that online security and fraud prevention comes top in what Brits think banks should guarantee, with 60% wanting 'peace of mind' when using cards online. The survey also discovered that consumers are keen to play a much more proactive role in managing their personal finances. New ways of managing their card services before, during and after a payment; how, when and where cards are used and the ability switch your card 'on' and 'off' to create extra vigilance against fraud - are all important to today's card user. The omnibus
Brookfield Asset Management 2018 Second Quarter Results Conference Call And Webcast13.7.2018 16:04 | Pressmeddelande
Date: Thursday, August 9, 2018 Time: 11:00 a.m. (Eastern Time) TORONTO, July 13, 2018 (GLOBE NEWSWIRE) -- Second Quarter Conference Call You are invited to participate in Brookfield Asset Management's 2018 Second Quarter Conference Call & Webcast on Thursday, August 9, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at https://event.on24.com/wcc/r/1795914/64490BD29FBE43FAF176E3AF02943920. For those unable to p
NP3 och Diös gör bytesaffär i Gävle13.7.2018 12:15 | Pressmeddelande
NP3 och Diös gör en bytesaffär i Gävle. Syftet är att ytterligare stärka närvaron i respektive geografiska fokusområden. Diös köper 5 centrala samhällsfastigheter av NP3 och NP3 köper 13 industri- och bygghandelsfastigheter av Diös. Tillträde sker per den 3 september 2018. De 13 industri- och handelsfastigheter som NP3 förvärvar motsvarar en uthyrningsbar yta om cirka 80 000 kvadratmeter i områdena Näringen och Sörby Urfjäll. De största hyresgästerna är Ahlsells, Trelleborg och Swedol. Fastighetsvärdet uppgår till 345 mkr. De 5 samhällsfastigheterna Diös förvärvar motsvarar en total uthyrningsbar yta om 17 000 kvadratmeter, där den största fastigheten är en projektfastighet i närheten av Alderholmen, vilken kommer inrymma ett nytt kontor för Trafikverket. Tillträdet avseende den fastigheten sker under kvartal 1 2019. Övriga hyresgäster är Migrationsverket och två friskolor. Fastighetsvärdet uppgår till 300 mkr. Transaktionerna sker i bolagsform och kommer att redovisas under tredje kva
Squirrels Research Labs Announces Acorn Cryptocurrency Acceleration Hardware12.7.2018 21:04 | Pressmeddelande
NORTH CANTON, Ohio, July 12, 2018 (GLOBE NEWSWIRE) -- Squirrels Research Labs today announced Acorn, a new hardware component that improves efficiency and effectiveness of cryptocurrency mining. "We developed a piece of hardware called Acorn that increases the effectiveness of existing GPU mining operations without adding a significant cost," Squirrels president David Stanfill said. "This is a brand new concept that's never been done before." Acorn works in sync with GPUs to offload work that typically creates bottlenecks in mining. It performs the work much faster, resulting in an increase in overall mining efficiency. Initially three models will be available: CLE-101, CLE-215 and CLE-215+. Each model uses high-performance FPGA chips from Xilinx Inc. (NASDAQ:XLNX) in an M.2 slot to perform the least GPU-efficient parts of cryptocurrency mining. All Acorn models work with memory-intensive algorithms like Ethash and CryptoNight V1. The 215 and 215+ models work with both memory-intensive
NRT & Sightline Secure Multi-Year Exclusive Agreement with Ocean Resort Casino12.7.2018 19:30 | Pressmeddelande
Atlantic City's newest resort casino opens with a seamless customer experience for omni-channel solutions LAS VEGAS, July 12, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. and Sightline Payments, LLC (together "NRT Sightline") today announced that Ocean Resort Casino in Atlantic City, N.J. opened its doors with the full suite of NRT Sightline solutions, including Play+, QJ self-serve kiosks, Cash+ ATM, credit and debit advances, VisuaLimits table signs and analytics, and the full suite of NCC credit and compliance solutions. "NRT Sightline has invested in cutting-edge technology that gives us a competitive advantage, and we look forward to our long-term partnership with this world-class technology leader," said Alan Greenstein, Chief Financial Officer of Ocean Resort Casino. "Ocean Resort Casino is Atlantic City's showcase property for a truly omni-channel guest experience. As the lines that separate cash and cashless commerce converge in gaming, our solutions remove friction from the
VeriTransfer(TM) Unveils the First Known Proof-of-Concept for a Blockchain Enabled Firearms Licence Verification and Ownership Transfer12.7.2018 17:43 | Pressmeddelande
Blockchain Enabled Firearms Solution Ensures Instant Verification of Ownership and Safe Transfer While Maintaining Data Privacy TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- VeriTransfer(TM) today announced the completion of its Proof-of-Concept ("POC") of the first publicly announced Blockchain enabled solution that decentralizes the process of storing the ownership rights and transfer of firearms. VeriTransfer(TM) is also pleased to announce that it will donate a percentage of all future revenues or the proceeds from any future sale of the company towards foundations whose mission is to end gun violence and build safer communities. The Gun Epidemic & The Economic Impact The United States hosts 4.4% of the world's population, but almost 50% of the 644 million civilian-owned guns globally are located in the U.S. Disturbingly, more American citizens have died as a result of gunshots in the U.S. since 1968 than on the battlefield of all the wars in American history from 1175 to 2015. In add
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum